Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
LL-37 disrupts microbial membranes through its amphipathic α-helical structure and additionally modulates host immunity via formyl peptide 2 (FPR2) signalling, neutrophil chemotaxis, and innate immune cytokine regulation.
02
Research applications
- Antimicrobial peptide research (bacterial, viral, fungal models)
- Host-defence and innate immunity research
- Sepsis and inflammation research
- Anti-HIV research (early-stage)
Evidence at a glance
What's behind this profile
3 citations · 2016–2021
- Review
- 2
- Other
- 1
Narrative or systematic reviews; no primary data.
Studies that did not match the categories above.
Publication years
- 16
- 17
- 18
- 19
- 20
- 21
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 0 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity
2016
Fabisiak A et al. · Pharmacological Reports
- Model
- Narrative review of LL-37 biology and therapeutic potential
- Sample
- N/A (review)
Reviewed LL-37 as a broad-spectrum antibiotic and immunomodulator with chemotactic activity across immunological, respiratory, gastrointestinal, and skin systems.
Therapeutic Potential of Cathelicidin Peptide LL-37, an Antimicrobial Agent, in a Murine Sepsis Model
2020
Nagaoka I et al. · International Journal of Molecular Sciences
- Model
- In vivo — murine cecal ligation and puncture (CLP) sepsis model
- Sample
- Not reported in abstract
LL-37 was associated with protection in the murine sepsis model through suppression of macrophage pyroptosis, enhancement of neutrophil extracellular trap formation, and antimicrobial microvesicle release.
Antimicrobial Peptide, LL-37, And Its Potential As An Anti-HIV Agent
2021
Vera-Cruz A et al. · Clinical and Investigative Medicine
- Model
- Narrative review of LL-37 antimicrobial activity with focus on HIV inhibition
- Sample
- N/A (review)
Reviewed LL-37's broad antimicrobial properties and inhibition of HIV infection in primary T cells, framing its potential as a multipurpose prevention technology.
Evidence caveats
- Clinical use of synthetic LL-37 is investigational and not FDA-approved for any indication at the time of writing.
- Most efficacy data are from in vitro and rodent studies; human pharmacology evidence is limited to small early-phase studies in specific dermatology and infection contexts.
04
Storage and handling
Store under controlled laboratory conditions with batch and preparation details recorded.
- Synthetic LL-37 is hygroscopic — store under controlled humidity per supplier guidance.
- Maintain batch and supplier documentation for antimicrobial research.
- Research-only inventory; not for human use.